In early 2023, Montréal InVivo entered into an agreement with the Montréal firm B2B/2GO to provide structured business networking opportunities throughout the year to members of the Quebec life sciences ecosystem. The agreement will be rolled as of this week starting with the event on risk management (in collaboration with CRIM and Innovitech).

As soon as you register for the event, you will receive a link to activate your profile on the business networking platform and you will be able to schedule quick and efficient meetings with other event participants. It’s a simple and effective way to meet potential business partners and make good use of your time on the sidelines of organized activities in the ecosystem. Keep in mind that it’s the same platform that will be used throughout the year, including EFFERVESCENCE. So, once your profile has been entered, there is no need to re-enter it. If you haven’t already done so, I would encourage you to go ahead and create your profile.

In addition, the federal government has just unveiled its policy on rare diseases in Montréal! I am very pleased with this choice because it clearly demonstrates the leadership position held by Quebec in the field of rare diseases. This leadership is reflected in the field thanks to the hard work of several patient organizations. I can’t name them all, of course, but the Regroupement québécois des maladies orphelines (RQMO) immediately comes to mind.

This leadership is also demonstrated by the academic and clinical research conducted in Quebec and in Montréal, as well as by the leading-edge companies that have demonstrated in the past the extraordinary value of the technologies developed right here. Montréal InVivo is proud to play its role in convening and engaging within this ecosystem thanks to the generosity, unwavering commitment and unparalleled quality of its rare disease project committee.

In addition to the strategic plan for rare diseases unveiled almost a year ago, the committee has continued its work throughout the year and is finalizing a series of tools that will help better plan the arrival of and access to all the new therapies emerging in this field. Thank you to all the members of the committee!